Adjuvant cisplatin-vinorelbine chemotherapy has been shown to be eŠective in patients with completely resected non-small cell lung cancer (NSCLC) in several Phase III trials, but not yet in the Japanese population. Pharmacists are expected to assist patients with completion of adjuvant chemotherapy. The aim of this retrospective study was to evaluate the compliance with and safety of adjuvant cisplatin-vinorelbine chemotherapy in Japanese patients and to evaluate the contribution of pharmacists to completion of treatment. Thirty-four patients with NSCLC who received adjuvant cisplatin-vinorelbine chemotherapy at Kyorin University Hospital between January 2006 and June 2015 were reviewed. The treatment schedule comprised cisplatin 80 mg/m 2 on day 1 and vinorelbine 25 mg/m 2 on days 1 and 8 every 3 weeks. Four 3-week cycles were planned. A pharmacist provided guidance to all patients and monitored them for adverse eŠects thereafter. The pharmacist intervened with advice to doctors as necessary. The 4 cycles were administered in 67.6％ of cases. There were no treatment-related deaths. The main grade 3 or 4 toxicities were neutropenia (76.5％) and anorexia (38.2％). The most common reason for discontinuation and dose reduction was anorexia. There were 56 instances of pharmacist intervention. In total, 96.4％ of the pharmacist interventions were implemented by doctors, which included administration of an antiemetic on 15 occasions and hot fomentation for prevention of vasculitis on 7 occasions. Adjuvant cisplatin-vinorelbine chemotherapy was tolerated by most patients but was discontinued because of adverse events in some. Pharmacist intervention aids completion of planned chemotherapy and management of treatment-related adverse events.
INTRODUCTION
Lung cancer is the most common malignancy and the leading cause of cancer-related death worldwide. 1) The most eŠective treatment for early-stage non-small cell lung cancer (NSCLC) is surgical resection. However, a proportion of patients with lung cancer develop recurrence, even after curative resection. 2) Adjuvant chemotherapy has been used to reduce the recurrence rate based on evidence from several Phase III trials and a meta-analysis. The JBR.10 trial showed that adjuvant cisplatin-vinorelbine chemotherapy improved 5-year survival rate by 15％ in patients with stage IB or II disease. 3) The Adjuvant Navelbine International Trialist Association (ANI-TA) trial reported that 5-year overall survival im-proved by 8.6％ in the chemotherapy arm and was maintained at 7 years (8.4％). 4) Furthermore, a meta-analysis by the Lung Adjuvant Cisplatin Evaluation group demonstrated that cisplatin-based adjuvant chemotherapy improved survival in patients with stage II or III cancer 5) and subgroup analysis showed that cisplatin-vinorelbine chemotherapy was an eŠective regimen. 6) Therefore, cisplatin-vinorelbine chemotherapy is recognized as a standard adjuvant regimen, including in Japan, where guidelines recommend it for patients with NSCLC. However, the evidence for this recommendation is not based on data from the Japanese population and toxicity of adjuvant cisplatin-based chemotherapy is fatal in a proportion of cases. Therefore, there is a need to accumulate evidence on adjuvant cisplatin-based chemotherapy in Japanese patients.
Adjuvant cisplatin-vinorelbine chemotherapy is an eŠective regimen but is associated with a high rate of adverse events. 3, 4) Pharmacists can play an important role in supervising patients receiving adjuvant chemotherapy and helping them complete their planned treatment. Pharmacist intervention has been shown to beneˆt patients in a variety of settings. 7 9) However, data on how pharmacists can intervene and make a worthwhile contribution in patients receiving adjuvant chemotherapy are limited. The aim of the present study was to evaluate the eŠect of pharmacist intervention on the compliance and safety of adjuvant cisplatin-vinorelbine chemotherapy in patients with NSCLC.
MATERIALS AND METHODS

Patients and Study Design
This retrospective study was conducted at Kyorin University Hospital using medical records data. Three hundred and eightythree patients were diagnosed with stage II or IIIA NSCLC after surgical resection between January 2006 and June 2015. Each patient was pathologically staged according to the the 7th edition of the Union for International Cancer Control classiˆcation of TNM staging Thirty-four of the 383 patients received adjuvant cisplatin-vinorelbine chemotherapy after surgical resection. The protocol was approved by the Clinical Epidemiology Research Review Committee of Kyorin University Hospital (approval number 660) and the study was conducted in accordance with the Declaration of Helsinki.
The treatment schedule consisted of cisplatin 80 mg/ m 2 on day 1 and vinorelbine 25 mg/m 2 on days 1 and 8 every 3 weeks. Four 3-week cycles of chemotherapy were planned. Vinorelbine and cisplatin were administered in hospital on day 1, and patients could receive vinorelbine on day 8 on an inpatient or outpatient basis. Antiemetic drugs were used in accordance with the guidelines during the study period. A combination of ramosetron and dexamethasone was used initially as antiemetic drugs, aprepitant was introduced in February 2010, and ramosetron was changed to palonosetron in September 2011 on the recommendation of the pharmacist. Drug doses were reduced and treatment was discontinued if deemed necessary by the attending physician. The doses of vinorelbine and cisplatin were reduced to 70 80％ of the initial planned dose. Laboratory tests were usually performed weekly. A pharmacist provided guidance to all patients before administration of the drugs, monitored them for adverse eŠects, and liaised with the attending physicians as necessary. The doctors consulted a pharmacist for advice when needed. A pharmacist was on the ward for about half a day or as required until December 2014. Since January 2015, a pharmacist has been on the ward full-time. During the study, there were two pharmacists, who had more than 10 years of pharmacy experience and more than 5 years of involvement in this study. One of them obtained certiˆcation as an oncology pharmacist under the Japanese Society of Pharmaceutical Health Care and Sciences during the investigation period.
Evaluation Data on patient characteristics, compliance with chemotherapy, reasons for treatment discontinuation and dose reduction, adverse events, and pharmacist intervention during the study period were collected. Adverse events were evaluated according to the National Cancer Institute Common Terminology Criteria version 4.0. The patients' symptoms were evaluated by doctors or pharmacists.
RESULTS
Patient Characteristics
The characteristics of the 34 patients are shown in Table 1 . Most of the patients (n＝21, 62％) had stage IIIA disease and the rest had stage IIA or IIB disease. The most frequent histological type was adenocarcinoma (n＝26, 76％). Thirty patients (88％) had a performance status of 0, and all patients had a performance status less than 2. Most of the patients had not undergone epidermal growth factor receptor mutation status testing during the study period. Lobectomy was the most common type of resection performed (n＝29, 85.3％).
Chemotherapy Table 2 shows patient compliance with chemotherapy. Twenty-three (67.6％) of the 34 patients received all 4 planned cycles of cisplatin and vinorelbine. Treatment was discontinued in 11 patients (32.4％). During theˆrst cycle, 8 patients (23.5％) were not able to receive vinorelbine on day 8. Reduction of cisplatin and vinorelbine doses were required in 19 patients (55.9％) and 18 patients (52.9 ％), respectively. A missing vinorelbine dose on day 8 was recorded as a dose reduction. Table 3 shows the reasons for discontinuation of treatment and dose reduction; all were related to adverse events, the most common of which was anorexia.
Toxicity There were no treatment-related deaths. Hematologic and biochemical toxicities are shown in Table 4 . Twenty-six patients (76.5％) deve- 1％) , which warranted discontinuation of treatment in 2 cases. Nonhematologic toxicities are shown in Table 5 . Anorexia and nausea were the most frequent toxicities in 13 patients (38.2％). Vasculitis was also a frequent tox-icity, resulting in discontinuation of treatment in 3 patients.
Pharmacist Intervention There were 56 instances in which the pharmacist intervened. The pharmacist's recommendation was implemented by the doctor in 54 cases (96.4％). The intervention was active (recommendation from the pharmacist to a doctor) in most cases (n＝49, 87.5％), but there were some instances of passive intervention (consultation of the pharmacist by a doctor; n＝7, 12.5％). Figure  1 shows details of the active interventions. The most frequent recommendation was for an antiemetic, most often metoclopramide (n＝6). Dexamethasone and olanzapine were recommended in 3 cases each. Other antiemetics suggested were proton pump inhibitor (n＝2) and aprepitant (n＝1). Hot fomentation for prevention of vasculitis and pain at the infusion site was suggested in 7 cases.
Pharmacist intervention was focused mainly on management of the adverse eŠects of adjuvant chemotherapy, but also included some postoperative complications. For example, the pharmacist recommended analgesics for neuralgia (n＝3) and antitussive (n＝1). Passive interventions consisted of consultations regarding the adequacy of chemotherapy at the end of infusion (n＝4), whether tinnitus is a side eŠect of chemotherapy (n＝1), whether a particular supplement aŠects chemotherapy (n＝1), and whether the dose of dexamethasone should be decreased in a patient with diabetes mellitus (n＝1).
DISCUSSION
No treatment-related deaths occurred during this study of adjuvant cisplatin-vinorelbine chemotherapy in Japanese patients with NSCLC, but there were some treatment discontinuations and dose reductions because of adverse events.
Adjuvant cisplatin-vinorelbine chemotherapy was tolerated by the majority of patients, and 23/34 patients (67.6％) completed all 4 planned treatment cycles. This completion rate is higher than that reported in the JBR.10 study (48％) 3) and in the AN-ITA study (50％ and 49％, for cisplatin and vinorelbine, respectively). 4) Grade 3 or 4 neutropenia was observed in 76.5％ of patients, which is similar to the rates reported in JBR.10 (73％) and ANITA (85％). However, grade 3 or 4 anorexia (38.2％) and nausea (38.2％) were more frequent in the present study than in JBR.10 (10％ and 10％, respectively) and in ANITA (15％ and 27％). Anorexia was the most frequent reason for discontinuation of treatment, so management of this adverse eŠect appears to be important for completion of 4 cycles of vinorelbine and cisplatin. Pharmacist intervention in patients receiving adjuvant cisplatin-vinorelbine chemotherapy was almost solely for management of adverse events. To date there have been no reports on pharmacist intervention in these patients. Anorexia was the most frequent reason for interruption of chemotherapy and was almost always caused by nausea. Control of nausea is an important factor in enabling completion of all 4 cycles of chemotherapy. Three patients in the study developed grade 3 nausea during theˆrst cycle of chemotherapy, which improved to grade 1 when olanzapine was administered on the recommendation of the pharmacist. All 3 patients were able to complete their 4 cycles of chemotherapy. From January 2015 onwards, there has been a full-time pharmacist on the ward at Kyorin University Hospital, and since then, a total of 5/5 patients have all completed 4 cycles of chemotherapy, albeit at reduced doses. A fulltime pharmacist constantly monitors adverse events, so adverse events can be immediately noticed and quick action can be taken. In addition, a full-time pharmacist is better able to deal with adverse events in collaboration with doctors and nurses than a parttime pharmacist. In particular, anorexia was the most common reason for discontinuation and the pharmacist was able to adequately manage this by proactively introducing antiemetics not frequently used by doctors such as olanzapine. Moreover, a relationship of trust can be established by long-term contact between pharmacist and patient. As a result, patients are able to report subjective symptoms to the pharmacist immediately, before the symptoms worsen. Theseˆndings suggest that the contribution of the pharmacist is important for completion of adjuvant chemotherapy.
There are several Japanese reports on the feasibility of adjuvant cisplatin-vinorelbine chemotherapy in patients with completely resected NSCLC. 10 13) In a Phase II study by Sonobe et al., 10) the 3-year relapsefree survival rate was 55.0％. Furthermore, Kenmotsu et al. 11) demonstrated the feasibility of adjuvant cisplatin-vinorelbine chemotherapy and a study by Shukuya et al. 12) conˆrmed its safety and good compliance. There is also some evidence that split doses of cisplatin and vinorelbine improve safety and achieve good compliance in Japanese patients. 13) However, there is still no consensus regarding the ideal adjuvant chemotherapy regimen for Japanese patients with NSCLC, and it is necessary to accumulate an evidence base for cisplatin-based adjuvant chemotherapy in the Japanese population. Here we have reported on the compliance, safety, reasons for discontinuation, and role of the pharmacist in administration of adjuvant cisplatin-vinorelbine chemotherapy in Japanese patients with completely resected NSCLC.
The present study has several limitations. First, it was a retrospective, single-center study with a small sample size. Second, we could not compare the rates of completion of all 4 cycles of chemotherapy with and without pharmacist intervention. However, in clinical practice, it would be considered unethical for a pharmacist not to assist with administration of chemotherapy and management of adverse eŠects. Therefore, we opted to describe the role of the pharmacist in this setting in detail. Third, theˆnal outcome of the intervention should include improved frequency of the symptoms, but we could not evaluate whether or not there was any improvement.
